IL23A and viral infectious disease: To test this hypothesis, we evaluated phenotypic differences among mice that were intranasally administered recombinant IL-23 (rIL-23) plus low dose polyinosinic-polycytidylic acid (poly I:C, a mimic of viral infection), rIL-23 plus diesel exhaust particles (DEPs), or phosphate-buffered saline (PBS) control treatment.